Q3 EPS Estimates for Dare Bioscience Raised by HC Wainwright

Dare Bioscience, Inc. (NASDAQ:DARE) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings estimates for shares of Dare Bioscience in a research note issued on Friday, August 14th. HC Wainwright analyst D. Tsao now forecasts that the biotechnology company will post earnings of $0.10 per share for the quarter, up from their previous estimate of $0.09. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Dare Bioscience’s Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $1.31 EPS.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.00 million. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%.

DARE has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dare Bioscience in a research report on Friday, July 17th. Benchmark reaffirmed a “buy” rating on shares of Dare Bioscience in a report on Monday. Finally, Wall Street Zen raised shares of Dare Bioscience to a “hold” rating in a report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dare Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Dare Bioscience Stock Performance

Shares of DARE opened at $0.81 on Tuesday. The stock has a 50-day moving average of $1.72 and a two-hundred day moving average of $1.87. The stock has a market cap of $12.22 million, a P/E ratio of -1.16 and a beta of 1.08. Dare Bioscience has a one year low of $0.77 and a one year high of $3.78.

Institutional Investors Weigh In On Dare Bioscience

A number of large investors have recently modified their holdings of the company. LPL Financial LLC acquired a new stake in Dare Bioscience during the 4th quarter worth $28,000. Raymond James Financial Inc. increased its holdings in shares of Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 13,650 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Dare Bioscience in the 3rd quarter valued at $37,000. 6.70% of the stock is owned by hedge funds and other institutional investors.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.